Case report
The proband is a 2.9 kg female infant born at 37 weeks gestation by cesarean section for decreased fetal movement and breech presentation. She was noted to be dysmorphic with frontal bossing, dolichocephaly, down-slanting palpebral fissures, deep sunken eyes and simplified ears ( Figure 1a ). Other features included redundant skin with reduced skeletal muscle and subcutaneous tissue giving her a senile appearance, scoliosis, joint contractures, long and deformed feet and pronounced arachnodactyly with hyperextensible fingers and toes. In addition, she had a weak cry, high-arched palate, generalized hypotonia, shallow respirations and a single horizontal palmar crease. Her cardiac examination revealed a hyperactive precordium, systolic clicks, a diastolic regurgitant murmur at the left parasternal border and a high-pitched systolic murmur at the apex. Ophthalmologic examination revealed lens dislocation and iridodonesis bilaterally. A chest radiograph revealed cardiomegaly, thin ribs and eventration of the right hemidiaphragm (Figure 1b) . Bone radiographs showed slender and bowed long bones and lumbar scoliosis, while abdominal ultrasound revealed right sided hydronephrosis. Transthoracic echocardiography demonstrated dilation of all cardiac chambers and prolapsing atrioventricular valves with redundant tissue bilaterally (Figures 1d and e) . There was moderate mitral and mild tricuspid valve regurgitation, while the semilunar valves were dysplastic and moderately regurgitant at birth. The aortic root was severely dilated and measuring 23 mm at the sinuses of Valsalva (z-score>5) (Figures 1c-e) . In addition, there was severe dilation of the pulmonary root up to 40 mm (z-score>5) (Figure 1f ). The ventricles were dilated and demonstrated dyssynergic contraction with hyperdynamic systolic function of the left ventricle.
On the basis of the above findings, the diagnosis of neonatal Marfan syndrome (nMFS) was made and a blood sample was sent to the John Welsh Cardiovascular Diagnostic Laboratory (Houston, TX, USA) for mutation analysis of fibrillin-1 (FBN1). Comprehensive open reading frame/splice investigation of the 65 exons contained in the FBN1 gene was performed. The sequence analysis identified a heterozygous 3256T>C nucleotide change in exon 26 (Figure 2a ). This nucleotide change was not observed in 200 ethnic-matched control subjects and predicts an amino-acid substitution of cysteine to arginine at the highly conserved position 1086 (C1086R) (Figure 2b ). Analysis of parents genomic DNA revealed normal sequence, consistent with a de novo mutation in this region. The sequence analysis of the proband's DNA also identified three benign homozygous polymorphisms (1415G>A, IVS56 þ 17C>G, IVS60À113C>A), which have not been associated with disease. No other alteration in the FBN1 coding region was identified in the patient or her parents.
The patient developed heart failure and respiratory distress that necessitated positive pressure ventilation despite ongoing therapy with diuretics and captopril. At 6 weeks, she was switched to losartan, an angiotensin II type I receptor blocker that has potential role in the treatment of Marfan's syndrome. 1 The losartan dose was titrated for blood pressure response (final dose 1.6 mg kg À1 per day) without adverse effects. However, mitral valve regurgitation progressed rapidly and a cardiac magnetic resonance imaging demonstrated massive dilation of the left atrium interfering with ventilation. Surgical intervention was contemplated, but in view of the patient's poor overall prognosis the family decided against further escalation of her care. The treatment with losartan was withdrawn and the patient died from cardiorespiratory failure at 69 days of age. Post-mortem examination confirmed severe quadrivalvar dysplasia with myxoid degeneration of the valve leaflets ( Figure 1g ) and cystic medial degeneration of the proximal great arteries, while elastic staining showed elastic fiber fragmentation and disarray (Figures 1h and i) .
Discussion
Heterozygous mutations in the FBN1 gene cause MFS, a connective tissue disorder manifested by abnormalities in the skeletal, ocular and cardiovascular system. 2 nMFS represents the severe end of the spectrum of MFS, which is clinically distinguished from the other forms by its severe mitral and/or tricuspid valve insufficiency that relentlessly progress, leading to heart failure and death in the first 2 years of life. 3 nMFS is usually caused by de novo mutations in a region of the FBN1 gene on chromosome 15q21.1 between exons 24 and 32. [4] [5] [6] FBN1 consists of 65 exons encoding a 2871 amino-acid protein that contains 47 epidermal growth factor (EGF)-like repeats. Forty-three of these EGF modules satisfy the consensus sequence for calcium binding (cb-EGF) that mediates protein-protein interactions. Each of these domains contains six highly conserved cysteine residues (C) that form three disulfide bridges, important for conferring conformational stability and resistance to proteolytic degradation. 7 Substitutions of one of the C in the cb-EGF-like domains represent the most common form of mutations causing MFS. 8, 9 Here, we report a newborn with severe MFS and a novel missense mutation of FBN1 in the third Figure 1 Neonatal Marfan syndrome: the patient had dolichocephaly, frontal bossing, deep sunken eyes and simplified ears as well as redundant skin at the neck and pronounced arachnodactyly (a). Chest X-Ray at birth demonstrates cardiomegaly, thin ribs, scoliosis and eventration of the right hemidiaphragm (b). Magnetic resonance angiogram (MRA) demonstrates a markedly dilated aortic root at the sinuses of Valsalva, while the ascending aorta, aortic arch and major arch branches are of normal caliber (c). two-dimensional echocardiography from the four-chamber view and short-axis parasternal view demonstrate a dilated aortic root, prolapsing mitral valve and dilated pulmonary trunk, respectively (d and f). Magnetic resonance imaging from bright-blood cine loops demonstrate a complex, regurgitant jet characterized by dark signals on the left atrial side of the mitral valve (white arrows in e) during mid-systole. The aortic root, left ventricle, left atrium and pulmonary trunk are all markedly dilated (c-f). Close-up view of the mitral valve upon opening the left ventricle. The leaflets are irregular, bumpy and show myxoid degeneration (g). Elastic staining of pulmonary trunk and aorta demonstrate cystic medial wall degeneration (black asterisks in h and i, respectively), as well as elastic fragmentation and disarray. These histological changes were more prominent in the pulmonary trunk than the aorta ( Â 400 original magnification, elastic stain). Ao, aorta, PA; pulmonary artery; LV, left ventricle; LA, left atrium; MV, mitral valve.
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L Kochilas et al cysteine of exon 26 and within one of the cb-EGF-like domains of FBN1 known to be important for the stabilization of fibrillin molecules. An amino-acid substitution of cysteine to tyrosine at this position (1086) has been previously reported in a patient with nMFS. 10 The mutation in our patient predicts a cysteine substitution by arginine at amino-acid residue 1086 (C1086R). The absence of this mutation in the parents DNA confirms this variant as a disease-associated mutation.
Recent studies with mouse models of MFS demonstrate that disease-associated FBN1 mutations cause dysregulation of cytokine function due to excessive signaling by the transforming growth factor-b (TGF-b). 9 These data support the contention that increased TGF-b signaling contributes to selected manifestations of MFS, including the myxomatous changes of the atrioventricular valves and the aortic root dilation, and TGF-b signaling antagonism was shown to rescue both manifestations of MFS in mouse. 11 The antihypertensive agent losartan, an angiotensin II type 1 receptor blocker, which also antagonizes TGF-b signaling, has been shown to be effective in normalizing aortic root dimensions in FBN1 deficient animals when treated postnatally at a young age. 1 Its effect on the atrioventricular valve phenotype has not been tested yet, but based on the shared pathogenetic mechanism, it is a promising treatment for this severe and early lethal manifestation of nMFS. We treated our patient with losartan and the medication was well tolerated without adverse effects. However, in the presence of severe mitral regurgitation, the patient's clinical condition continued to deteriorate rapidly leading to her demise from cardiorespiratory failure 3 weeks later, thus not allowing any safe conclusions in this setting.
In conclusion, we present a newborn with severe MFS due to a novel mutation in FBN1. As our understanding of the pathophysiology of MFS has evolved away from the static model of structural weakness of the extracellular matrix to the more dynamic concept of dysregulated matrix-cell interaction, the stage is set for novel therapeutic approaches tailored to the underlying genotype. One of the most promising new therapies for MFS is the use of angiotensin II receptor I blockers. In our case, the poor prognosis of nMFS was not altered by losartan, but the treatment period was too short to allow for effective tissue remodeling. In that regard, the potential of losartan may be limited in neonates with severe MFS as angiotensin antagonism in this age can affect renal development and function. As new therapies continue to emerge for the treatment of this severe disorder, characterization of each patient's genetic background may become an important consideration for selecting patients and predicting response to therapy.
No funding provided and no conflict of interest. Figure 2 The automated sequencing analysis demonstrates the novel heterozygous 3256T>C variant leading to the nonsynonymous change, which has been identified in the proband, but not in her parents (a). The amino-acid conservation analysis identified that the C1086R variant modified a highly conserved amino acid in fibrillin-1 (FBN1) (b).
FBN-1 mutation in neonatal Marfan
syndrome L Kochilas et al
